Genetic markers in thyroid neoplasia

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 2, 2001, Pages 493-513

  Puxeddu, E ^a   Fagin, J A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; CALCITONIN; CALCIUM; CATECHOLAMINE; DNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NEURTURIN; PARATHYROID HORMONE; PENTAGASTRIN; PERSEPHIN; PROTEIN TYROSINE KINASE; THYROGLOBULIN; THYROTROPIN RECEPTOR; THYROXINE DEIODINASE; TRANSFORMING GROWTH FACTOR BETA;

CHROMOSOMAL LOCALIZATION; CHROMOSOME 10Q; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE; HUMAN; ONCOGENE RET; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THYROID CARCINOMA;

EID: 0034957846     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70196-1     Document Type: Article

References (143)

1. A novel deletion in the ret proto-oncogene found in sporadic thyroid carcinoma
2. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-ret receptor complex
3. N-ras mutation in poorly differentiated thyroid carcinomas: Correlation with bone metastases and inverse correlation to thyroglobulin expression
4. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases
5. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area
6. A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
7. Familial nontoxic multinodular goiter locus maps to chromosome 14q, but does not account for familial nonmedullary thyroid cancer
8. Ret proto-oncogene mutations in inherited and sporadic medullary thyroid cancer
9. Ret mutations in exon 13 and 14 of FMTC patients
10. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A
11. Full activation of MEN 2B mutant ret by an additional MEN 2A mutation or by ligand GDNF stimulation
12. Neurturin responsiveness requires a GPI-linked receptor and the ret receptor tyrosine kinase
13. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
14. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid
15. An allelotype of papillary thyroid cancer
16. A gene predisposing to familial thyroid tumors with cell oxiphilia maps to chromosome 19p13.2
17. Ras oncogene mutations in thyroid tumors: Polymerase chain reaction-restriction fragment length polymorphism analysis from paraffin-embedded tissues
18. GDNF differentially stimulates ret mutants associated with multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease
19. The different ret-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype
20. Single missense mutation in the tyrosine kinase catalytic domain of the ret proto-oncogene is associated with multiple endocrine neoplasia type 2B
21. Alimentary-tract ganglioneuromatosis: A major component of the syndrome of multiple endocrine neoplasia, type 2B
22. Multiple endocrine neoplasia, type 2B
23. Identification of the Cys634Tyr mutation of the ret proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis
24. MEN 2 mutations affecting specific extracytoplasmic cysteines exert a dual effect on the ret receptor
25. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma
26. Progress in genetic screening of multiple endocrine neoplasia type 2A: Is calcitonin testing obsolete?
27. Biology of disease: Multiple endocrine neoplasia syndromes revisited
28. The human Ha-ras oncogene induces genomic instability in murine fibroblast within one cell cycle
29. Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-ras
30. Overexpression of c-MET/HGF receptor gene in human thyroid carcinomas
31. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland
32. Ret proto-oncogene mutations associated with sporadic cases of medullary thyroid carcinoma
33. The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International ret mutation consortium
34. Heterogeneous mutation of the ret proto-oncogene in subpopulations of medullary thyroid carcinoma
35. Low frequency of germline mutations in the ret proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma
36. Mutation in the ret proto-oncogene in sporadic medullary thyroid carcinoma
37. Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
38. A novel point mutation in the tyrosine kinase domain of the ret proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC
39. Point mutation within the tyrosine kinase domain of the ret proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors
40. Editorial: Familial papillary thyroid cancer - Many syndromes, too many genes?
41. Ret proto-oncogene in the development of human cancer
42. The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors
43. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas of the thyroid gland
44. Molecular pathogenesis of tumors of thyroid follicular cells
45. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity
46. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas
47. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults
48. Predisposition to neoplastic transformation caused by gene replacement of H-ras1
49. The epidemiology of thyroid carcinoma
50. Oncogenic rearrangements of the ret proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident
51. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A
52. Pathogenesis of medullary thyroid carcinoma
53. Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis
54. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A: An 18-year experience
55. Germline dinucleotide mutation in codon 883 of the ret proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
56. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary thyroid carcinomas
57. A mutation in the ret proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
58. Ret mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia
59. A duplication of 12 bp in the critical cysteine rich domain of the ret proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A
60. Biological properties of ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype
61. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations
62. Unique association of p53 mutations with undifferentiated but hot with differentiated carcinomas of the thyroid gland
63. Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells
64. The ret/PTC oncogene in papillary thyroid carcinoma
65. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas
66. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF
67. Influence of cellular DNA content on survival in differentiated thyroid cancer
68. DNA aneuploidy in follicular adenomas of the thyroid gland
69. Ras oncogene mutations in benign and malignant thyroid neoplasms
70. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms
71. Novel germline ret proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): Mutation analysis in Japanese patients with MTC
72. A GPI-linked protein that interacts with ret to forma candidate neurturin receptor
73. High prevalence of ret rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident
74. Analysis of ret proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas
75. Familial papillary carcinoma of the thyroid
76. The practical management of multiple endocrine neoplasia
77. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis
78. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: Exclusion of linkage fo ret, MNG1, and TCO in 56 families
79. The demise of follicular carcinoma of the thyroid gland
80. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
81. Familial occurrence of papillary thyroid carcinoma
82. Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome
83. Deletion-insertion mutation encompassing ret codon 634 is associated with medullary thyroid carcinoma
84. Somatic mutations in the ret proto-oncogene in sporadic medullary thyroid carcinoma
85. The identification of false positive responses to the pentagastrin stimulation test in ret mutation negative members of MEN 2A families
86. Thyroid cancer: Impact of therapeutic modalities on prognosis
87. Persephin, a novel neurotrophic factor related to GDNF and neurturin
88. The two genes generating ret/PTC3 are localized in chromosomal band 10qll.2
89. Two germline missense mutations at codon 804 and 806 of the RET proto-oncogene in the same allele in a patient with MEN 2B without codon 918 mutation
90. Preferential induction of ret/PTC1 rearrangement by X-ray irradiation
91. Specific mutations of the ret proto-oncogene are related to disease phenotype in MEN 2A and FMTC
92. Characterization of ret proto-oncogene 3′ splicing variants and polyadenylation sites: A novel C-terminus for ret
93. H-ras proto-oncogene mutations in human thyroid neoplasms
94. Point mutations of ras oncogene are an early event in thyroid tumorigenesis
95. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ele1 and ret genes in radiation-induced thyroid carcinomas
96. Prevalence of microsatellite and minisatellite instability in thyroid carcinomas from children exposed to radiation after the Chernobyl nuclear accident
97. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
98. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells
99. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome)
100. Ataxia-telangiectasia with papillary carcinoma of the thyroid
101. Galectin-3 is a presurgical marker of human thyroid carcinoma
102. A comparative study of flow cytometry and histopathologic findings in thyroid follicular carcinomas and adenomas
103. Familial occurrence of differentiated, nonmedullary thyroid carcinoma
104. Ret proto-oncogene mutations in thyroid carcinomas: Clinical relevance
105. Cancer incidence in rive continents: Comparability and quality of data
106. The physical map of the human ret proto-oncogene
107. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma
108. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome
109. Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: Multiple endocrine neoplasia type 3
110. The association between thyroid neoplasia and intestinal polyps
111. Somatic mutations of the ret proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence
112. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease
113. Detection of a germline mutation at codon 918 of the ret proto-oncogene in French MEN 2B families
114. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms
115. Molecular mechanisms of ret activation in human neoplasia
116. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
117. Development of papillary thyroid carcinomas secondary to tissue-specific expression of ret/PTC1 oncogene in transgenic mice
118. 3: A novel rearranged version of the ret proto-oncogene in a human thyroid papillary carcinoma
119. The trk and ret tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line
120. Ret proto-oncogene mutations in French MEN 2A and FMTC families
121. Prevalence and parental origin of de novo ret mutations in MEN 2A and FMTC
122. The association of pheochromocytoma with carcinoma of the thyroid gland
123. Germline mutation of ret codon 883 in two cases of de novo MEN 2B
124. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal benign thyroid
125. Familial papillary carcinoma of the thyroid
126. Presence of mutations in all three ras genes in human thyroid tumors
127. Distinct multiple ret/PTC rearrangements in multifocal papillary thyroid neoplasia
128. Mechanism of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations
129. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains
130. Structure and expression of ret transforming gene
131. Down-regulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories
132. Ret/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
133. Serum thyroglobulin measurement: Utility in clinical practice
134. Characterization of a multicomponent receptor for GDNF
135. Functional receptor for GDNF encoded by the c-ret proto-oncogene
136. Type II multiple endocrine neoplasia (Sipple syndrome): Study of a family
137. Up-regulation of vascular endothelial growth factor (VEGF) and down-regulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors cell lines
138. Increased methotrexate resistance and dhrf gene amplification as a consequence of induced Ha-ras expression in NIH3T3 cells
139. Studies of allelic loss in thyroid tumors reveals major differences in chromosomal instability between papillary and follicular carcinomas
140. Relevance of ret proto-oncogene mutations in sporadic medullary thyroid carcinoma
141. Mutations of codon 918 in the ret proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma
142. Somatic and MEN 2A de novo mutations identified in the ret proto-oncogene by screening of sporadic MTCs
143. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling